公开(公告)号：US20130039918A1

公开(公告)日：2013-02-14

申请号：US13642143

申请日：2011-02-21

申请人： Sung Ho Ryu ,  Pann-Ghill Suh ,  Mi-Sook Lee ,  Wan-Uk Kim

发明人： Sung Ho Ryu ,  Pann-Ghill Suh ,  Mi-Sook Lee ,  Wan-Uk Kim

IPC分类号： A61K38/18 ,  C07H21/02 ,  A61P9/00 ,  A61P9/10 ,  A61P25/00 ,  A61P25/28 ,  A61P1/04 ,  A61P17/02 ,  A61K38/02 ,  C07K16/22 ,  C07H21/00 ,  A61P37/06 ,  A61P3/10 ,  A61K48/00 ,  A61P17/06 ,  A61P35/04 ,  A61P35/00 ,  A61P29/00 ,  A61P19/02 ,  A61P13/12 ,  A61P9/12 ,  A61P27/06 ,  A61P1/16 ,  A61K31/7088 ,  A61K31/713 ,  C12N15/63 ,  C12Q1/68 ,  G01N33/566 ,  G01N21/64 ,  A61K39/395 ,  A61P27/02 ,  C12N15/12

CPC分类号： A61K38/18

摘要： This disclosure relates to an angiogenesis-related pharmaceutical composition using connective tissue growth factor, more particularly to a pharmaceutical composition for promoting angiogenesis containing the connective tissue growth factor or a pharmaceutical composition for inhibiting angiogenesis containing at least one selected from the group consisting of polypeptide, antibody and a compound binding to connective tissue growth factor. The fragment of connective tissue growth factor protein, which was found out in the present invention, is a binding region to FPRL1, effectively induces FPRL1-specific ERK phosphorylation, activates FPRL1 to increase intracellular Ca2+ concentration, and finally, effectively induces angiogenesis, and thus, the fragment of connective tissue growth factor may be useful for a pharmaceutical composition for promoting angiogenesis, while polypeptide, antibody or a compound binding to the fragment of connective tissue growth factor protein may be useful for a pharmaceutical composition for inhibiting angiogenesis.

摘要翻译： 本公开涉及使用结缔组织生长因子的血管生成相关药物组合物，更具体地涉及用于促进含有结缔组织生长因子的血管生成的药物组合物或用于抑制血管生成的药物组合物，其含有选自多肽， 抗体和与结缔组织生长因子结合的化合物。 在本发明中发现的结缔组织生长因子蛋白的片段是与FPRL1的结合区域，有效诱导FPRL1特异性ERK磷酸化，激活FPRL1以增加细胞内Ca2 +浓度，最终有效诱导血管生成，因此 结缔组织生长因子的片段可用于促进血管发生的药物组合物，而多肽，抗体或结合组织生长因子蛋白的片段的化合物可用于抑制血管生成的药物组合物。

公开(公告)号：US08859496B2

公开(公告)日：2014-10-14

申请号：US13642143

申请日：2011-02-21

申请人： Sung Ho Ryu ,  Pann-Ghill Suh ,  Mi-Sook Lee ,  Wan-Uk Kim

发明人： Sung Ho Ryu ,  Pann-Ghill Suh ,  Mi-Sook Lee ,  Wan-Uk Kim

IPC分类号： A61K38/18

CPC分类号： A61K38/18

摘要： This disclosure relates to an angiogenesis-related pharmaceutical composition using connective tissue growth factor, more particularly to a pharmaceutical composition for promoting angiogenesis containing the connective tissue growth factor or a pharmaceutical composition for inhibiting angiogenesis containing at least one selected from the group consisting of polypeptide, antibody and a compound binding to connective tissue growth factor. The fragment of connective tissue growth factor protein, which was found out in the present invention, is a binding region to FPRL1, effectively induces FPRL1-specific ERK phosphorylation, activates FPRL1 to increase intracellular Ca2+ concentration, and finally, effectively induces angiogenesis, and thus, the fragment of connective tissue growth factor may be useful for a pharmaceutical composition for promoting angiogenesis, while polypeptide, antibody or a compound binding to the fragment of connective tissue growth factor protein may be useful for a pharmaceutical composition for inhibiting angiogenesis.

摘要翻译： 本公开涉及使用结缔组织生长因子的血管生成相关药物组合物，更具体地涉及用于促进含有结缔组织生长因子的血管生成的药物组合物或用于抑制血管生成的药物组合物，其含有选自多肽， 抗体和与结缔组织生长因子结合的化合物。 在本发明中发现的结缔组织生长因子蛋白的片段是与FPRL1的结合区域，有效诱导FPRL1特异性ERK磷酸化，激活FPRL1以增加细胞内Ca2 +浓度，最终有效诱导血管生成，因此 结缔组织生长因子的片段可用于促进血管发生的药物组合物，而多肽，抗体或结合组织生长因子蛋白的片段的化合物可用于抑制血管生成的药物组合物。